
Pantherics: Innovating therapy through peripheral GABAA receptor modulation.
Pantherics was founded with the core mission of innovating therapeutic solutions through the modulation of peripheral GABAA receptors. The company's vision is to revolutionize the treatment of respiratory conditions, particularly asthma, by developing novel therapies that offer better control and fewer side effects compared to existing treatments. Pantherics' primary product is an oral new chemical entity (NCE) designed to target peripheral GABAA receptors, aiming to provide a groundbreaking approach to asthma management.
Notable affiliated individuals and investors include leading experts in pharmacology and respiratory medicine, though specific names are not disclosed. Pantherics has achieved significant milestones in preclinical development, demonstrating the potential efficacy and safety of their lead compound. The overall impact of Pantherics' work could be substantial, offering a new therapeutic avenue for millions of asthma patients who struggle with uncontrolled symptoms and frequent hospitalizations.

Areteia Therapeutics
areteiatx.com

Respira Therapeutics

Aero Therapeutics

Health Care Originals

PanTheryx
pantheryx.com

Pneuma Respiratory

Peroxitech Therapeutics

Epalex
epalex.com

Respirics

Aer Therapeutics

Function Therapeutics
functiontx.com

Path BioAnalytics

Precision Theranostics

Pulmatrix
pulmatrix.com

VitalFlo
vitalflohealth.com
Companies similar to Pantherics include Areteia Therapeutics, Respira Therapeutics, Aero Therapeutics and Health Care Originals.
Pantherics was founded in 2019.
Pantherics' headquarters is located in Milwaukee, WI, US.
Pantherics' most recent funding round was for $255.8k (USD) in August 2022.
As of Aug 11, 2022, Pantherics has raised a total of $518.6k (USD).
Pantherics has 5 employees as of Feb 4, 2024.